Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
隨着旭化成宣佈控制超過90%的calliditas therapeutics，決定申請將其普通股票從納斯達克斯德哥爾摩市場退市，並將其美國存託憑證從納斯達克全球精選市場退市。
Following The Announcement By Asahi Kasei That It Controls Over 90% Of Calliditas Therapeutics Has Resolved To Apply For Delisting Its Common Shares From Nasdaq Stockholm And Its American Depositary Shares From The Nasdaq Global Select Market
隨着旭化成宣佈控制超過90%的calliditas therapeutics，決定申請將其普通股票從納斯達克斯德哥爾摩市場退市，並將其美國存託憑證從納斯達克全球精選市場退市。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間